The Virtual Poster Hall featured 98 research posters. Members may view posters by logging in here. If you are not a member, you may join here. 

Abstracts are available for public viewing on our Abstracts Page.

Dr. Morag Park is a Professor in the Departments of Oncology and Biochemistry at McGill University. She is a Knight of the Ordre national du Québec, Fellow of the Royal Society of Canada, Fellow of the Canadian Academy of Health Sciences, James McGill Distinguished Professor and holds the Diane and Sal Guerrera Chair in Cancer Genetics. Dr. Park received a B.Sc. with first class honors from the University of Glasgow, a Ph.D. at the Medical Research Council Virology Institute in Scotland and completed postdoctoral training at the National Institutes for Cancer Research in Washington DC, US. She was the Director of the Molecular Oncology Group at the McGill University Health Centre (2006-8), Scientific Director of the Institute of Cancer Research for the CIHR (2008-13), co-chair of the Canadian Cancer Research Alliance (2008-2010) and is now Director of the Goodman Cancer Institute (2013-present). She is a recipient of a Canadian Cancer Research Alliance Award (2015) for Exceptional Leadership in Cancer Research. Most recently she is a recipient of the Canadian Cancer Society Robert L. Noble Prize (2017), the Quebec Breast Cancer Foundation Grand Prix Scientifique (2019), and the Club de Recherches Cliniques du Québec Michel Sarrazin Award (2021).

Dr. Park is a research leader in the field of receptor tyrosine kinases (RTK) and mechanisms of oncogenic activation of RTKs in human cancers. She cloned the Met RTK, which is now a key therapeutic target in oncology. She established the Breast Cancer Functional Genomics Group at McGill. She has pioneered studies of the breast tumour and immune microenvironment in triple negative breast cancer (TNBC). She was the elected chair of the Tumour Microenvironment Network of the American Association for Cancer Research (2015-2017). She has more than 230 publications an h-index of 82.

Neuroendocrine tumor (NET) disease is both rare and complex. About 15,000 new patients are diagnosed each year in the U.S. – which means many medical professionals will encounter neuroendocrine tumors only a few times in their careers.

The North American Neuroendocrine Tumor Society (NANETS) is a society of over 400 multidisciplinary medical professionals committed to the support of colleagues in diagnosing and treating NET patients, as well as furthering the cause of NET science and education in North America. With new research, technologies and practices emerging, the landscape of NET treatment is rapidly changing.

NANETS will offer a special recording-only registration for all who were unable to attend the 2021 Virtual Symposium. Watch for complete details on how to register, coming soon.

Here's How to Access the Virtual Symposium:

HOW TO LOG IN You can enter the Virtual Regional Conference beginning Tuesday, November 2, 10:00am EDT. Visit https://nanetsvirtual2021.vfairs.com/ Sign in with the email address you used to register for the conference.

You are only allowed to login with one device at a time. If you leave the conference – please log back in the same way. NANETS will announce how to access Conference content after the live program. If you are not yet a NANETS member, JOIN TODAY at nanets.net Please note, you must be registered for the Virtual Symposium for access.

Covid Statement:
The recent surge in COVID-19 infections across the U.S. from the delta variant and the transmission of COVID-19 to children has made it challenging for large numbers of medical professionals to convene safely in person and continue to protect themselves, their patients, families, and communities. Based on the ever-changing COVID-19 trajectory, and the feedback of our membership, presenting faculty and staff, NANETS has decided pivot to a fully virtual event for the 2021 NANETS' Annual Multidisciplinary NET Symposium previously scheduled for an in-person event in Chicago, IL.

While we are all disappointed in having to pivot again this year to a Virtual event we are hopeful that we will be able to successfully transition as we did in 2020 where we had over 500 participants and so much positive feedback following the event. NANETS truly appreciates your understanding and is excited to have you take part in this educational
virtual program. 

Currently registered attendees will automatically be registered for the virtual symposium. All registration rates will remain the same. NANETS is cancelling the late registration fee option. The standard fee will apply going forward, with no late registration penalty. Registration will remain open until the live symposium date.

Each year, NANETS provides research grants to young investigators doing preeminent work in the field of NET research. The grants available through NANETS were established to both support new research initiatives and welcome young and eager scientific minds to the NET community. Currently, NANETS has three grants available: the Basic/Translational Science Investigator (BTSI) the NANETS Clinical Investigator Scholarship (NCIS) and the NANETS Theranostics Investigator Grant (NTIG). These annual grants support innovative research initiatives and encourage young researchers and scientific clinicians to become NET specialists.

The application deadline for 2018 research grant submissions is Wednesday, June 13, 2018.

Basic/Translational Science Investigator (BTSI)

The BTSI grant is available to individuals who are within the first five years of their faculty appointment and are predominantly focused on lab-based, basic/translational research. Click here for more information and to submit an application.

NANETS Clinical Investigator Scholarship (NCIS)

The NCIS grant emphasizes both the professional development of the scientific clinician (whose time is primarily dedicated to patient care) and the potential of the project to directly impact NET patients. Click here for more information and to submit an application.

NANETS Theragnostics Investigator Grant (NTIG)

The NTIG is awarded to an applicant who is focused on research with the potential to advance and expand the use of theragnostics in the treatment of NET patients. This award may be granted to researchers performing basic, translational or clinical research in theragnostics as it relates to NETs. Click here for more information and to submit and application.